Drugs in Dev. Obstetrics/Gynecology (Women’s Health)
Phase II/ Phase III
Lead Product(s) : SHR7280
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : SHR7280 is a drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Leiomyoma-associated with Menorrhagia.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
July 05, 2022
Lead Product(s) : SHR7280
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pentosan Polysulfate Sodium
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase II/ Phase III
Sponsor : TCM Biotech International Corp.
Deal Size : Inapplicable
Deal Type : Inapplicable
Radiation Cystitis Treated With Pentosan Polysulfate Sodium Trial
Details : Pentosan Polysulfate Sodium is a Other Small Molecule drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Cystitis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 18, 2022
Lead Product(s) : Pentosan Polysulfate Sodium
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase II/ Phase III
Sponsor : TCM Biotech International Corp.
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Progesterone
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase II/ Phase III
Sponsor : Watson Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Progesterone is a Hormone drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Polycystic Ovary Syndrome.
Product Name : Undisclosed
Product Type : Hormone
Upfront Cash : Inapplicable
February 22, 2018
Lead Product(s) : Progesterone
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase II/ Phase III
Sponsor : Watson Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : D-Chiroinositol
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Evaluation of the Mixture Myoinositol:D-chiro-inositol 3.6:1 in Women With Polycystic Ovary Syndrome
Details : D-Chiroinositol is a Dietary Supplement drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Polycystic Ovary Syndrome.
Product Name : Undisclosed
Product Type : Dietary Supplement
Upfront Cash : Inapplicable
June 28, 2017
Lead Product(s) : D-Chiroinositol
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Vitamin B12
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase II/ Phase III
Sponsor : Tribhuvan University Teaching Hospital, Institute of Medicine | NORCE Norwegian Research Centre AS | Sykehuset Innlandet HF
Deal Size : Inapplicable
Deal Type : Inapplicable
Vitamin B12 Supplementation During Pregnancy on Cognitive Development
Details : Cobalamin is a Vitamins/Minerals/Inorganic Salts drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Pregnancy.
Product Name : Undisclosed
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
March 07, 2017
Lead Product(s) : Vitamin B12
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase II/ Phase III
Sponsor : Tribhuvan University Teaching Hospital, Institute of Medicine | NORCE Norwegian Research Centre AS | Sykehuset Innlandet HF
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Digoxin
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Digoxin is a Other Small Molecule drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Pre-Eclampsia.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 02, 2017
Lead Product(s) : Digoxin
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study To Investigate The Effect Of A Natural Dietary Supplement On Peri-Menopausal Symptoms
Details : This drug candidate is currently being evaluated in phase II/ phase III clinical studies for the treatment of Menopause.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
July 14, 2015
Lead Product(s) : Undisclosed
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Misoprostol
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Misoprostol is a Other Small Molecule drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Pregnancy.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 24, 2014
Lead Product(s) : Misoprostol
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sildenafil Citrate
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase II/ Phase III
Sponsor : ZonMw
Deal Size : Inapplicable
Deal Type : Inapplicable
The Dutch STRIDER (Sildenafil TheRapy In Dismal Prognosis Early-onset Fetal Growth Restriction)
Details : Sildenafil is a Other Small Molecule drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Fetal Growth Retardation.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 28, 2014
Lead Product(s) : Sildenafil Citrate
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase II/ Phase III
Sponsor : ZonMw
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Meloxicam
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Assessment of a Vaginal Ring With Meloxicam in the Treatment of Dysmenorrhea
Details : Meloxicam is a Other Small Molecule drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Dysmenorrhea.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 02, 2014
Lead Product(s) : Meloxicam
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
